Full text is available at the source.
Abstract
Economic evaluation of tirzepatide, semaglutide, and liraglutide for obesity treatment is necessary due to their high cost.
- Subcutaneous tirzepatide, semaglutide, and liraglutide are potential treatments for adults with overweight or obesity without diabetes.
- Cost-effectiveness analysis is needed to inform resource allocation for these therapies in Iran.
- The evaluation will focus on the short-term economic impacts of these medications.
Simplified